Morningstar2d
Investors who lost money on ESSA Pharma Inc.(EPIX) should contact The Gross Law Firm about pending Class Action - EPIX
masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone; (ii) accordingly, masofaniten in combination with enzalutamide was less effective in treating ...
Morningstar3d
Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA
Emmett et al. Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901). Annals of Oncology ...
ascopubs.org4d
Sensitive tissue-based detection of AR-V7 and other androgen receptor alterations using combined DNA/RNA comprehensive genomic profiling.
Homologous recombination deficiency signature (HRDsig+) and the genomic landscape of clinically advanced prostate carcinoma (CAPC). This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary ...
ascopubs.org4d
NSD2 inhibition as a therapeutic approach for treatment-induced neuroendocrine prostate cancer.
The significance of androgen receptor signaling pathway in mCRPC patients receiving olaparib monotherapy or combined treatment with abiraterone. Circulating tumor cell expression analysis from the ...
Daily Mail4d
Doctors reveal the VERY surprising triggers that may be behind prostate cancer as epidemic surges 25% in four years to become the most common in Britain
Now, men with this diagnosis can live for a decade or longer with new treatments, including drugs such as abiraterone, enzalutamide, apalutamide and darolutamide that block androgen receptors in ...